Related Experiment Video
Updated: Aug 24, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
What are the chances? Evaluating risk and benefit information in consumer health materials
1Middlesex College University of Western Ontario London, Ontario N6K 2C8 Canada. jburkell@uwo.ca
Abstract:
Much consumer health information addresses issues of disease risk or treatment risks and benefits, addressing questions such as "How effective is this treatment?" or "What is the likelihood that this test will give a false positive result?" Insofar as it addresses outcome likelihood, this information is essentially quantitative in nature, which is of critical importance, because quantitative information tends to be difficult to understand and therefore inaccessible to consumers. Information professionals typically examine reading level to determine the accessibility of consumer health information, but this measure does not adequately reflect the difficulty of quantitative information, including materials addressing issues of risk and benefit. As a result, different methods must be used to evaluate this type of consumer health material. There are no standard guidelines or assessment tools for this task, but research in cognitive psychology provides insight into the best ways to present risk and benefit information to promote understanding and minimize interpretation bias. This paper offers an interdisciplinary bridge that brings these results to the attention of information professionals, who can then use them to evaluate consumer health materials addressing risks and benefits.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio
For example, in a clinical trial evaluating a...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Relative Risk
Hazard Rate
Framing Effects
